ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
JACC Identifies DEFER With 5 Year Outcomes As Landmark Trial
The
Journal of the American College of Cardiology has recognized the five year
follow up results of the DEFER (Deferral Versus Performance of PTCA in
Patients Without Documented Ischemia) as one of the studies that had the
greatest impact on cardiology in 2007, according to an article entitled
"Highlights of the Year in JACC" by Anthony N. DeMaria, MD, et al. (JACC
Vol. 51, No. 4, 2008 January 29, 2008:490-512)
Initially published in the May 29, 2007, issue of the peer-reviewed
journal, DEFER concluded that patients treated based on fractional flow
reserve (FFR) results had achieved long-term outcomes equal, or superior,
to patients who underwent stenting solely based on angiographic evidence.
The study's investigators measured FFR using PressureWire(R), a diagnostic
tool developed by Radi Medical Systems AB.
Dr. Nico Pijls, the study's principal investigator, said, "From the
DEFER study and other recent publications, it has become clear that the key
issue in deciding which lesions should be stented is knowledge about
whether a stenosis is responsible for ischemia. We are glad that JACC has
recognized this study that demonstrates the importance of FFR and its role
in interventional cardiology."
FFR expresses maximum achievable blood flow in a coronary artery with
abnormal stenosis as a fraction of maximum blood flow in the absence of a
stenosis. FFR is 100% specific in identifying which lesions are actually
causing the flow restriction and may be treated.
"The DEFER data was, and continues to be, an important topic of
discussion among cardiologists," said Jim Archetto, Chief Operating Officer
of Radi Medical Systems, Inc. "There is a lot of uncertainty in
interventional cardiology when it comes to determining whether or not a
stent is necessary. Measuring FFR is the only way physicians can determine
with precision that a suspect lesion requires treatment."
As an adjunct to DEFER, authors have designed a new 1000 patient study,
Fractional Flow Reserve Versus Angiography for Multivessel Evaluation
(FAME) (American Heart Journal Volume 154, Number 4). The objective of this
groundbreaking, multicenter, randomized clinical trial is to compare
angiographic guidance versus fractional flow reserve (FFR) to determine
which coronary lesions to stent in patients with multivessel coronary
disease.
The primary end point of the study is a composite of major adverse
cardiac events, including death, myocardial infarction, and repeat coronary
revascularization, at 1 year.
About Radi Medical Systems AB
Radi Medical Systems AB (Radi) develops, manufactures and sells medical
devices designed to improve patient care. The company's pioneering work in
the field of interventional cardiology has resulted in market-leading
intravascular sensors and hemostasis management and radiology devices. Radi
works closely with medical practitioners to develop solutions that address
clinical needs, as well as provide clinical education support. Founded in
1988, Radi employs more than 350 people globally and has representation in
more than 40 countries. The company is based in Uppsala, Sweden, and
maintains a U.S. headquarters in Wilmington, Mass. For more information,
visit http://www.radi.se.
Radi Medical Systems AB
http://www.radi.se
JACC identificã amâna cu 5 ani ca reper rezultatele judecatã - JACC Identifies DEFER With 5 Year Outcomes As Landmark Trial - articole medicale engleza - startsanatate